FOXP3+ Regulatory T Cells And Age-Related Diseases
February 2021
in “
FEBS Journal
”
Studysummary This review discusses potential immune therapies targeting regulatory T cells for age-related diseases and emphasizes the need for further research to translate these therapies into clinical practice.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document reviewed the role of FOXP3+ regulatory T cells (Tregs) in age-related diseases, emphasizing their importance in maintaining immune balance and their potential in therapeutic applications. Tregs were crucial in promoting hair-follicle regeneration and maintaining homeostasis in various tissues. Their imbalance with Th17 cells contributed to chronic inflammation in the elderly, leading to diseases like cancer and cardiovascular disorders. Clinical trials explored Treg-targeting antibodies for conditions such as type 1 diabetes, though potential adverse effects required attention. The review highlighted the need for further research to enhance the safety and specificity of Treg-based therapies and suggested that understanding Treg dynamics and targeting specific pathways could restore immune homeostasis and treat age-related conditions.
